B. Douglas Smith is Associate Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, and is on the active staff of Johns Hopkins Hospital. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed an internship, residency, and chief residency at Strong Memorial Hospital in Rochester, New York. At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies.
Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them into biology-based treatment approaches for patients with AML, CML, and MDS. He has developed collaborations with several laboratory-based physician-scientists and has help to translate differentiation-based strategies, small molecule inhibitors of signal transduction pathways (including, FLT3 mutated AML, raf kinase, ras kinase, and bcr-abl), and immunomodulatory approaches. Many of these trials share the common theme on studying the impact of the treatment on the leukemic stem cell in hopes of limiting these cells’ roles in treatment failure.
Dr. Smith serves on the NCCN Guideline panels for both AML and CML and as guest editor for numerous journals including Journal of Clincal Oncology, Leukemia, Clinical Cancer Research, Leukemia Research, and others. In addition, he is an active member of American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research.